Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161615 · ClinicalTrials.gov registry record · Phase 3
MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder
A Phase 3 study of Bursitis and Acute Tendonitis, sponsored by MEDRx USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT01161615 is a Phase 3 study of Bursitis and Acute Tendonitis that has completed, run by MEDRx USA. The registered enrollment target is 350 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT01161615, a Phase 3 study of Bursitis and Acute Tendonitis, has completed, sponsored by MEDRx USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MRX-7EAT
Study Locations (20)
Florida
- - Daytona Beach
- - Fort Lauderdale
- - Gulf Breeze
- - Orlando
- - West Palm Beach
Indiana
- - Avon
- - Fishers
- - Franklin
- - Greenfield
- - Muncie
California
- - Chico
- - Mission Hills
- - Palm Springs
- - San Diego
Colorado
- - Aurora
- - Colorado Springs
- - Denver
Arizona
- - Chandler
- - Phoenix
Arkansas
- - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01161615
The ClinicalTrials.gov registry entry for NCT01161615 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MEDRx USA, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bursitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01161615 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Indiana, California.
Frequently Asked Questions
What is clinical trial NCT01161615 about?
NCT01161615 is a clinical study titled "MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder". A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder.
What is the current status of trial NCT01161615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2010-07. Estimated completion is 2011-06.
What conditions does trial NCT01161615 study?
This clinical trial studies the following conditions: Bursitis, Acute Tendonitis.
What interventions are being tested in trial NCT01161615?
The interventions under investigation include: Placebo (DRUG), MRX-7EAT (DRUG).
Who is sponsoring clinical trial NCT01161615?
This trial is sponsored by MEDRx USA, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01161615 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bursitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.